Breaking News, Collaborations & Alliances

Rigel & Kissei Enter Agreement

To develop & commercialize TAVALISSE in all current and potential indications in Japan, China, Taiwan & the Republic of Korea

Rigel Pharmaceuticals has entered into an exclusive license and supply agreement with Kissei Pharmaceutical Co. to develop and commercialize TAVALISSE™ in all current and potential indications in Japan, China, Taiwanand the Republic of Korea.  “Kissei is a leading Japanese pharmaceutical company with significant development experience and a track record of commercial success in Asian markets. Their commitment to develop TAVALISSE in ITP, and potential future indications in these territ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters